Treatment with CsnB reduced ESCC tumor growth, but both rapid growth and increased tumor size demonstrated that exogenous expression of IRF1 could considerably diminish the anticancer impact of CsnB in vivo (Fig. 5E–G). This evidence concerns the gene IRF1 and neoplasm.